Organization (Industry)
Vir Biotechnology, Inc.
ClinicalTrials.gov lists Vir Biotechnology, Inc. as lead sponsor of 22 trials. It has 22 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Vir Biotechnology, Inc.: 22 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 12 |
| Hepatitis B | 10 |
| Hepatitis B, Chronic | 10 |
| Hepatitis D | 4 |
| Hepatitis D, Chronic | 4 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 4 |
| 2024 | 1 |
| 2023 | 5 |
| 2022 | 6 |
| 2021 | 7 |
| 2020 | 9 |
| 2019 | 1 |
| 2018 | 1 |
Prediction, not a registry value: median of 34 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 15 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (22)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| VIR-2218 | Hepatitis D, Chronic | Phase 3 | 4 |
| VIR-2218 | Hepatitis D | Phase 3 | 4 |
| VIR-3434 | Hepatitis D | Phase 3 | 4 |
| VIR-3434 | Hepatitis D, Chronic | Phase 3 | 4 |
| Bulevirtide | Hepatitis D | Phase 3 | 2 |
Showing 5 of 22 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sotrovimab | 6 |
| Bulevirtide | 2 |
| PEGinterferon alfa-2a | 1 |
| PEMBROLIZUMAB | 2 |
| Fumarate, Tenofovir Disoproxil | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=16) | 36% on time (n=14) |
Journals published in (31)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 6 |
| JAMA | 4 |
| Annals of internal medicine | 3 |
| Drugs in R&D | 3 |
| Antimicrobial agents and chemotherapy | 2 |
Showing 5 of 31 journals.
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 68,556,000 | -437,987,000 | 455,966,000 |
| 2024 | 74,205,000 | -521,960,000 | 506,499,000 |
| 2023 | 86,180,000 | -615,061,000 | 579,720,000 |
| 2022 | 1,615,797,000 | 515,837,000 | 474,648,000 |
| 2021 | 1,095,415,000 | 528,584,000 | 448,006,000 |
| 2020 | 76,368,000 | -298,665,000 | 302,411,000 |
| 2019 | 8,091,000 | -174,683,000 | 148,472,000 |
| 2018 | 10,668,000 | -115,884,000 | 100,229,000 |
| 2017 | 2,708,000 | -69,852,000 | 62,512,000 |
| 2016 | not reported | not reported | not reported |
Financing and grant events (38)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-27 | Public offering | not disclosed | Sec extracted |
| 2026-02-27 | Public offering | 172,500,000 | Sec extracted |
| 2026-02-26 | Follow-on offering | 172,499,994 | Edgar offerings |
| 2026-02-26 | Public offering | not disclosed | Sec extracted |
| 2026-02-25 | Public offering | not disclosed | Sec extracted |
Showing 5 of 38 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (16)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 8 |
| University of Copenhagen | Co sponsors trial with | 2 |
| UK Research and Innovation | Co sponsors trial with | 2 |
| Kirby Institute | Co sponsors trial with | 2 |
| University of Minnesota System | Co sponsors trial with | 2 |
Showing 5 of 16 relationships.
Latest dated events (74)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02-27 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-27 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-26 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-26 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-25 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 74 events.
Biomarker capability evidence (13)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
| CYP3A4 | Trial collaborator | Named in trial exclusion criteria |
| CYP3A4 | Trial collaborator | Mentioned in trial text |
Showing 5 of 13 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.